Table 2.
Potential risk factors predicting recurrence beyond the pelvic cavity.
| Only within pelvic cavity (n = 134) | Beyond pelvic cavity (n = 130) | p | |
|---|---|---|---|
| Age (years), mean ± SD | 48.95 ± 10.51 | 48.42 ± 9.41 | 0.664 |
| FIGO 2009 staging, n (%) | 0.002 | ||
| I | 85 (63.43) | 57 (43.85) | |
| II | 46 (34.33) | 58 (44.62) | |
| III | 2 (1.49) | 11 (8.46) | |
| IV | 1 (0.75) | 4 (3.08) | |
| Staging categories, n (%) | 0.004 | ||
| Early | 61 (45.52) | 43 (33.08) | |
| Locally advanced | 70 (52.24) | 72 (55.38) | |
| Advanced | 3 (2.24) | 15 (11.54) | |
| Histological subtypes, n (%) | 0.879 | ||
| SCC | 107 (79.85) | 102 (78.46) | |
| ADC | 22 (16.42) | 24 (18.46) | |
| Adenosquamous carcinoma | 5 (3.73) | 4 (3.08) | |
| Histological differentiation, n (%) | 0.719 | ||
| Grade 1 | 9 (11.11) | 11 (13.58) | |
| Grade 2 | 42 (51.85) | 37 (45.68) | |
| Grade 3 | 30 (37.04) | 33 (40.74) | |
| Primary treatment regimens, n (%) | 0.005 | ||
| Only chemotherapy | 1 (0.75) | 0 (0) | |
| Only radiotherapy or CCRT | 27 (20.15) | 47 (36.15) | |
| Radiotherapy or CCRT plus chemotherapy | 4 (2.99) | 9 (6.92) | |
| Surgery with/without adjuvant therapy | 102 (76.12) | 74 (56.92) | |
| Surgical routes, n (%) | 0.908 | ||
| Laparoscopy | 41 (40.20) | 29 (39.73) | |
| Open surgery | 60 (59.41) | 44 (60.27) | |
| Surgical protocols, n (%) | 0.042 | ||
| Radical hysterectomy | 71 (68.93) | 61 (82.43) | |
| Others | 32 (31.07) | 13 (17.57) | |
| Ovarian reservation, n (%) | 0.364 | ||
| No | 57 (55.34) | 46 (62.16) | |
| Yes | 46 (44.66) | 28 (37.84) | |
| Adjuvant therapy before primary treatment regimens, n (%) | 0.543 | ||
| No | 114 (85.07) | 107 (82.31) | |
| Yes | 20 (14.93) | 23 (17.69) | |
| Definite adjuvant therapy before primary treatment regimens, n (%) | 0.050 | ||
| Chemotherapy | 20 (100.00) | 19 (82.61) | |
| Chemotherapy plus radiotherapy | 0 (0) | 4 (17.39) | |
| Adjuvant therapy after primary treatment regimens, n (%) | 0.340 | ||
| No | 87 (64.93) | 77 (59.23) | |
| Yes | 47 (35.07) | 53 (40.77) | |
| Definite adjuvant therapy after primary treatment regimens, n (%) | 0.012 | ||
| Chemotherapy | 21 (44.68) | 9 (17.31) | |
| Radiotherapy | 16 (34.04) | 27 (51.92) | |
| Chemotherapy plus radiotherapy | 10 (21.28) | 16 (30.77) | |
| DFS after primary treatment (months), median (range) | 15.92 (3.1–249.6) | 17.18 (4.3–174.5) | 0.191 |
ADC, adenocarcinoma; CCRT, concurrent chemoradiotherapy; DFS, disease-free survival; FIGO, the International Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; SD, standard deviation.
Bold values show the p values <l0.05.